Plain-English translation of NCT06697483 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial tests a personalized approach to maintenance therapy after stem cell transplant for multiple myeloma, a blood cancer. Your specific treatment plan—either alone or combined with —will be determined by your individual risk level and whether any cancer cells remain detectable after transplant. The goal is to find the right balance between the medication you receive and your own circumstances.
After stem cell transplant, patients need long-term treatment to keep the cancer from returning, but it's unclear whether everyone benefits from the same approach. This trial investigates whether personalizing the maintenance strategy—based on risk factors and disease markers specific to each patient—can improve long-term outcomes.
You likely qualify if…
You likely don't qualify if…
After you complete your stem cell transplant and initial response assessment, you will be assigned to take either as a single medication or combined with , depending on your individual risk profile and whether any cancer cells are still detectable. You will receive your assigned maintenance therapy and attend regular follow-up appointments to monitor how well you are doing and check for any side effects. The trial is conducted across multiple medical centers, so you may have the option of receiving care closer to home.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
China